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Squamous cell carcinoma (SCC) of the buccal mucosa is an aggressive oral cancer. It mainly
occurs in Central and Southeast Asia, and is closely related to the practice of tobacco smok-
ing and betel squid chewing. The high recurrence and low survival rates of buccal SCC require
our continued efforts to understand the pathogenesis of the disease for designing better ther-
apeutic strategies. We used proteomic technology to analyze buccal SCC tissues aiming at
identifying tumor-associated proteins for the utilization as biomarkers or molecular targets.
With the exception of alpha B-crystallin being substantially reduced, a number of proteins
were found to be significantly over-expressed in cancer tissues. These increased proteins
included glycolytic enzymes, heat-shock proteins, tumor antigens, cytoskeleton proteins,
enzymes involved in detoxification and anti-oxidation systems, and proteins involved in mito-
chondrial and intracellular signaling pathways. These extensive protein variations indicate that
multiple cellular pathways were involved in the process of tumorigenesis, and suggest that
multiple protein molecules should be simultaneously targeted as an effective strategy to coun-
ter the disease. n please check sentence n SCC antigen, G protein, glutathione S-transfer-
ase, manganese superoxide dismutase, annexins, voltage-dependent anion channel, cyclo-
philin A, stratifin and galectin 7 are candidates for targeted proteins. The present findings also
demonstrated that rich protein information can be produced by means of proteomic analysis
for a better understanding of the oncogenesis and pathogenesis in a global way, which in turn
is a basis for the rational designs of diagnostic and therapeutic methods.
Keywords: Biomarker / Buccal cancer / Mass spectrometry fingerprinting / Protein profile / Two-dimen-
sional-polyacrylamide gel electrophoresis
Received 23/12/03
Revised 27/1/04
Accepted 29/1/04
Proteomics 2004, 4, 000–000 1
1 Introduction
Oral cancers represent a major health problem worldwide
and are the most common forms of cancer in Central and
Southeast Asia. Squamous cell carcinoma (SCC) of the
tongue and the buccal mucosa is the most common type
of oral cancers. Buccal SCC tends to be more aggressive
than those originating in other parts of the oral cavity, with
a high rate of locoregional recurrence and poor survival
[1]. Epidemiologic studies suggested that the incidence
of oral SCCs is closely related to the practice of tobacco
smoking together with nut, lime and betel squid chewing
[2]. The major constituents of tobacco and betel squid are
believed to cause inflammation and DNA damage, which
may lead to malignant transformation. Traditionally, the
treatment of oral SCC consisted of surgery, combined
with postoperative radiotherapy and chemotherapy. Re-
search data suggested that early surgical intervention
and withdrawal from oral habits are beneficial to patient
survival [3]. With present clinical assessment and treat-
ment methods, patients are often diagnosed at late
stages and the survival rate has not improved substan-
tially. This highlights the necessity for continued efforts to
discover suitable biomarkers for early diagnosis of the
disease, and to understand its pathogenesis as a first
step in improving methods of treatment.
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We have recently identified tumor-associated proteins in
oral SCCs by means of proteomic technology. These
tumor-associated proteins can be further evaluated as
potential biomarkers for clinical diagnosis and as targeted
proteins for pathogenetic investigations. Following prote-
omic analysis of tongue SCC [4], the present study
focuses on proteomic variations in buccal SCC. Tumori-
genesis involves multiple pathological transformations,
leading to the alterations of proteins that play functional
roles in the process. Proteomic alterations should there-
fore, hold detailed information regarding the biology of the
disease. Our current findings demonstrated the involve-
ments of multiple pathways in buccal SCC, with a number
of tumor-related proteins showing changes in their
expressions. The discovery of these potential biomarkers
and molecular targets for cancer diagnostics and thera-
peutics has the potential to significantly change the clin-
ical approach and outcome of the disease.
2 Materials and methods
2.1 Tissue and sample preparation
Ten pairs of surgical specimens of primary SCC of buccal
mucosa and adjacent normal mucosa were collected
from Queen Mary Hospital (University of Hong Kong)
Hong Kong, China and stored in a deep freezer (2807C)
until use. The study was approved by the University’s
ethics committee. All patients gave their consent in writ-
ing for the donation of tissue and blood for research pur-
poses. The study included five male and five female
patients, whose ages ranged from 53 to 81 years. The
AJCC pathologic stages were 2 T1, 5 T2, and 3 T3.
Table 1 lists detailed histological data for the tissue sam-
ples used. Fig. 1 provides a representative histological
picture showing a pair of matched tissue samples side
by side. Overall, the tumor specimens contained 68 6
21% tumor cells. Total proteins were extracted from the
tissues according to a procedure described previously
[4]. The protein concentration of each sample was deter-
mined by the Bradford method and the protein samples
were stored at 2807C in aliquots.
2.2 2-DE
2-DE was carried out with Amersham Biosystems IPG-
phor IEF and Ettan Dalt six electrophoresis units (Amers-
hamBiosciences, Uppsala, Sweden) by following the pro-
tocol described previously [5]. Protein samples (150 ,
200 mg) extracted from tumor center and surrounding his-
tologically normal mucosa were applied to the 2-DE and
run side by side in pairs. Electrophoresis was performed
in triplicate for each sample pair to ensure reproducibility.
All gels were visualized by silver-staining [5].
2.3 Image analysis and MS peptide sequencing
Image acquisition and analysis were performed with an
ImageScanner (Amersham Biosciences) and ImageMas-
ter 2D Elite software (Amersham Biosciences) [5]. Com-
parisons were made between gel images of individual
tumor and control samples. Normalized volume differ-
ences were statistically calculated for all ten cases. Con-
sistently and significantly different spots were selected for
analysis with MALDI-TOF MS. Protein spots were cut out
of gels in small pieces and subjected to in-gel tryptic
digestion overnight [5]. Peptide mass spectra were
recorded and parameters for spectra acquisition were
used as stated previously [5]. In database protein match-
ing using MS-Fit (http://prospector.ucsf.edu/), 25 ppm or
better mass accuracy and MOWSE scores over 200 were
obtained in most of the analyses. Duplicate or triplicate
runs were performed to ensure an accurate analysis.
Western blotting was performed to confirm the specificity
of the identified proteins, if necessary.
Figure 1. Representative histo-
logical picture showing a pair of
matched tissue specimens side
by side.
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Table 1. Patient information and histological data for the tissue samples used
Patients Sex/age T Stage sample pairs Tumor
cells (%)
Normal
mucosal
cells (%)
Muscle
cells (%)
Connective tissue cells
lymphocytes, vessel
cells, fibroblasts (%)
1 Ma)/80 T1N0M0 Tumor (TCc)) 95 0 5 20
Mucosa (SMd)) 0 15 0 85
2 Fb)/53 T2N0M0 Tumor (TC) 95 0 0 5
Mucosa (SM) 0e) 30 30 40
3 F/69 T3N0M0 Tumor (TC) 50 0 0 50
Mucosa (SM) 0 0 0 100
4 F/77 T3N1M0 Tumor (TC) 70 0 0 30
Mucosa (SM) 0 5 35 60
5 M/70 T2N0M0 Tumor (TC) 75 5 0 20
Mucosa (SM) 0 15 70 15
6 M/81 T1N0M0 Tumor (TC) 95 0 0 5
Mucosa (SM) 0 10 60 30
7 F/74 T2N0M0 Tumor (TC) 70 0 0 30
Mucosa (SM) 0 0 20 80
8 M/75 T3N0M0 Tumor (TC) 50 0 0 50
Mucosa (SM) 15 0 30 55
9 F/72 T2N0M0 Tumor (TC) 50 0 5 45
Mucosa (SM) 0 20 0 80
10 M/62 T2N0 Tumor (TC) 30 0 10 60
Mucosa (SM) 0 0 0 100
The relative percentage (%) of cells was rounded up to 5%. Cells less than 5% were counted as 0.
a) M, male
b) F, female
c) TC, tumor center
d) SM, surrounding mucosa
e) Patient has positive margin, few cancer cells are found in the adjacent submucosa of the surgical margin.
2.4 2-D Western blotting
Protein samples were run on 2-D gels using identical condi-
tions as described for 2-DE in section 2.3. The separated
proteins in the corresponding areas from gels were trans-
ferred onto PUDF membranes and incubated overnight at
47CwithablockingbuffercontainingTBST (Tris-bufferedsa-
line, 0.1% Tween 20) and 5% nonfat dry milk. Membranes
were washed with TBSTand incubated with monoclonal or
polyclonal antibodies at a 1:500 or 1:1000 dilution for 1 h at
room temperature or overnight at 47C. After washing again
with TBST, the membranes were blotted with a secondary
antibody conjugated with horseradish peroxidase at a
1:10000 dilution for 1 h, and then detected by enhanced
chemiluminescence (Pierce, Rockford, IL, USA) for 1min.
3 Results
Figure 2 is a typical 2D gel image for the tumor tissue of
buccal SCC. More than 1200 protein spots were sepa-
rated in a 13616 cm gel, with Mr ranging from 10 to
200 kDa and pI from 4 to 10. Compared to the 600 protein
spots detected in tongue SCC [4], significantly more pro-
teins were observed in buccal SCC. Furthermore, the pat-
terns of the protein profiles between these two SCCs are
totally different, suggesting that different proteins and
functional pathways may be involved in the two cancers.
Highlighted in squares are the seven areas where signifi-
cant and consistent volume differences of protein spots
were found when comparisons were made between nor-
mal and tumor tissue samples. Except for one protein
(alpha B-crystallin, Cryst-B) that was almost below the
level of detection in tumor tissue, all other identified pro-
teins were substantially up-regulated in SCC samples.
Table 2 lists the proteins identified after in-gel digestion,
MALDI-TOF MS measurement and database searching.
Most of the matched peptide fingerprints had reasonable
sequence coverage, precise mass accuracy (, 25 ppm)
and high MOWSE scores (. 200). The majority of the
identified proteins are intact molecules after electropho-
resis! n Only three spots belong to cleaved or truncated
polypeptides as they appeared in areas of the 2-D
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Figure 2. An overview of the master 2-D gel
image for buccal SCC tissue. Highlighted in
squares are the seven areas where significant
and consistent differences were found in pro-
tein expression levels.
gels with Mr lower than the matched full-length proteins.
These three polypeptides are fragments of heat shock
protein 70 (HSP70), gamma-actin and cytokeratin 6B,
respectively. The protein identification of these three frag-
ments was justified by the fact that the matched peptides
are concentrated in certain parts of the protein
sequences.
Only three proteins were identified to have similar trends
of alteration in both tongue and buccal SCCs, with Cryst-
B being down-regulated and HSP27 and mitochondrial
ribosomal protein (MRP)-L13 being up-regulated in can-
cer tissues. It should be pointed out that the previously
identified protein, nuclear FMRP interacting protein 1, in
tongue SCC [4] is actually MRP-L13. This strongly over-
expressed protein spot consistently appeared in both
tongue and buccal tissues (Fig. 2, Area VII), but MS finger-
printing with trypsin-digested peptides did not produce a
satisfactory match with low sequence coverage and
MOWSE score [4]. Moreover, FMRP binding protein is
not involved in tumorigenesis [4]. We therefore used chy-
motrypsin instead of trypsin in the in-gel digestion! n The
resulting MS peptide fingerprint was satisfactorily
matched to protein MRP-L13 (Table 2). Figures 3–6 dis-
play the detailed protein alterations between SCC and
matched normal tissues. Compared to those in normal
tissue, all identified proteins, except Cryst-B, were found
to be significantly increased (11.5–9.1-fold) in SCC tis-
sue, while Cryst-B was dramatically decreased (-12.3-
fold) in cancer tissue. These over-expressed proteins can
be classified into several categories based on their func-
tions, including glycolytic enzymes, HSPs, detoxification
and anti-oxidation proteins, cytoskeleton proteins, pro-
teins involved in mitochondrial and intracellular signaling
pathways, and tumor antigens. Table 3 summarizes the
proteins and their functions, corresponding areas in the
2-D gel, and fold differences in buccal SCC compared to
the control.
Among the proteins identified, enolase, annexin A2 and
stratifin were found to have isoforms or cleaved polypep-
tides. While enolase had an isoform pattern (Fig. 3) similar
to that previously seen in other tissues, annexin A2 and
stratifin presented unique profiles of isoforms in buccal
cancer tissue (Figs. 6 and 7). As indicated in Fig. 6, four
spots, all elevated in cancer, were identified as stratifin,
with the two spots in the lowerMr region being C-terminal
truncated peptides as evidenced by MS fingerprinting se-
quencing. Detailed analysis of the MS spectra of tryptic
peptides with possible modifications found that lysines
at positions 68 and 77 can be methylated and threonine
at position 165 can be phosphorylated, accounting for the
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Table 2. Results of MALDI-TOF mass spectra and database searching for protein identification
Protein ID (Mr/pI) Peptides
matched
Sequence co-
verage (%)
Total mass
accuracy
(PPM)
MOWSE
score
ACC #
(NCBI)
Phosphoglycerate mutase (PM), (29 kD/6.7) 6–11 28–42 18 80990–94690 4505753
Enolase 1, (47 kD/7.0) 27–34 55–64 21–22 21280000 4503571
Pyruvate kinase (PK), (58 kD/8.0) 13 26 23 86660 478822M
Triosephosphate isomerase 1 (TPI), (27 kD/6.4) 11 37 19 1344 4507645
Glyceraldehyde-3-phosphate dehydrogenase
(GPDH), (36 kD/8.6)
8 20 20 378 7669492
Squamous cell carcinoma antigen (SCC-A),
(45 kD/6.3)
14–34 31–54 19–20 47310–
59720000
25005272
Guanine nucleotide binding protein (GNBP),
(35 kD/7.6)
8–9 25–26 15–17 2192–4487 5174447
Crystallin, alpha B (Cryst-B), (29 kD/6.8) 14 52 24 58410 4503057
Heat shock 27 kD protein (HSP27), (23 kD/6.0) 8–13 42–47 17–19 2148–35160 15928913
Heat shock 70 protein (HSP70) (fragment),
(71 kD/5.4)
11 17 11 23060 5729877
Aldo-keto reductase (AKR), (36 kD/7.7) 5 14 17 280 3493209
Glutathione S-transferase (GST), (23 kD/5.4) 7 43 8 2447 4504183
Annexin A1 (39 kD/6.6) 12 38 18 164500 4502101
Annexin A2 (39 kD/7.6) 8–38 20–66 12–22 402–2071000 4757756
Annexin A5 (36 kD/4.9) 8 23 18 6602 17391477
Manganese superoxide dismutase (MnSOD),
(23 kD/6.9)
7 30 16 1170 30841305
Voltage-dependent anion channel 2 (VDAC2),
(30 kD/6.8)
5 20 17 1160 15277577
Mitochondrial ribosomal protein L13 (MRP-L13),
(21 kD/9.2)
6 18 17 3090 1465270
Cyclophilin A (CyP-A), (18 kD/7.7) 7 17 13 275 6679439
Stratifin (14-3-3 sigma), (28 kD/4.7) 10–14 45–52 11–16 314–10060 5454052
Galectin 7, (15 kD/7.0) 21 83 16 1998 4504985
Actin, gamma (fragment), (42 kD/5.3) 4 11 25 216 71625M
Cytokeratin 6B (CK-6B) (fragment), (60 kD/8.1) 7 13 26 89 5031841
multiple spots of stratifin observed in the gel. 2-D West-
ern blotting images showing the isoform patterns of
annexin A2 in normal and SCC tissues are shown in
Fig. 7. Annexin A2 was obviously cleaved into different
polypeptides. Over-expression was detected in all spe-
cies except one low Mr fragment of the protein. Phos-
phorylated modification was also possible in some of
the high Mr species. Detailed MS spectral analysis
showed that phosphorylation can occur at Thr 44, Thr
48, Ser 294 and Ser 296, leading to isoforms with a
roughly 0.2 difference in pI.
4 Discussion
4.1 Aberrant cell growth in buccal SCC
The buccal mucosa is the most common site of oral SCC.
Malignant transformation of the buccal mucosa starts in
the squamous epithelium, the site susceptible to the sti-
muli of lime chewing and smoking. The normal squamous
epithelium needs to maintain a balance between cell pro-
liferation and cell death. The aggressive cell proliferation
or tumor formation is generally due to impaired cell apop-
tosis. The substantial over-expression of SCC antigen in
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Figure 3. Detailed alteration
patterns of proteins: phospho-
glycerate mutase (PM), triose-
phosphate isomerase (TPI), gly-
ceraldehydes-3-phosphate de-
hydrogenase (GPDH), enolase,
pyruvate kinase (PK), squamous
cell carcinoma antigen (SCC-A),
guanine nucleotide binding pro-
tein (GNBP), gamma actin and
cytokeratin 6B (CK-6B).
Figure 4. Detailed alteration patterns of proteins: crystal-
line alpha B (Cryst-B), HSP27, HSP70, aldo-keto reduc-
tase (AKR), and glutathione S-transferase (GST).
the present buccal SCC is the first of apoptotic imbal-
ance. SCC antigen, a member of the serine proteinase in-
hibitor family, inhibits apoptosis and migration of natural
killer cells by interacting with target proteinases [6–9]. Al-
though it is also expressed in the intermediate layer of the
normal squamous epithelium, the SCC antigen was found
to be highly up-regulated in various SCC cancers, includ-
ing those in the uterine cervix, lung, esophagus, head,
neck, and skin [8, 10]. Our current observation reinforces
the characteristic of SCC-antigen as a specific tumor
marker for SCC. Another sign of the aberrant cell prolifer-
ation in buccal SCC is the increased energy requirement
for cell differentiation, indicated by the upregulation of five
glycolytic enzymes (phosphoglycerate mutase, enolase,
pyruvate kinase TPI and glyceraldehydes-3-phosphate
dehydrogenase). Glycolysis is an energy generation path-
way, active in all differentiated cell types in multicellular
organisms. Elevated expression and activities of glycoly-
tic enzymes have been detected in various malignant
tumors such as lung, colon, liver and breast carcinomas
[11–13].
A significant increase in guanine nucleotide binding pro-
tein (GNBP) is also detected during malignant cell trans-
formation in buccal SCC. GNBP, also called G proteins,
belong to the Ras superfamily which consists of the Ras,
Rho, and Arf families. The protein members of this family
are widely involved in human tumorigenesis, either
through activating mutations or by over-expression to
induce cell transformation [14, 15]. It has been shown
that oncogenic mutations of Ras proteins, through farne-
syl protein transferase-catalyzed farnesylation, are preva-
lent in many human cancers [15], indicating that G pro-
teins are potential drug targets in cancer therapy where
Ras farnesylation can be blocked by introducing inhibi-
tors of farnesyl protein transferase [15].
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Table 3. Summary of altered proteins and their cellular functions, corresponding areas in the 2-D gel and volume differ-
ences (average values of triplicate measurements) in buccal SCC
Protein ID (Mr/pI) Area Function Change
(fold)
Phosphoglycerate mutase (PM), (29 kD/6.7) V Glycolysis, energy generation 13
Enolase 1, (47 kD/7.0) I Glycolysis, energy generation 12.3
Pyruvate kinase (PK), (58 kD/8.0) I Glycolysis, energy generation 13.3
Triosephosphate isomerase 1 (TPI), (27 kD/6.4) V Glycolysis, energy generation 11.6
Glyceraldehyde-3-phosphate dehydrogenase
(GPDH), (36 kD/8.6)
II Glycolysis, energy generation 12.6
Squamous cell carcinoma antigen (SCC-A),
(45 kD/6.3)
I Inhibits apoptosis and migration of natural
killer cells
14.2
Guanine nucleotide binding protein (GNBP),
(35 kD/7.6)
II Induces cell transformation through mutations 14.7
Crystallin, alpha B (Cryst-B), (29 kD/6.8) V Stress protein, chaperone, protection 212.3
Heat shock 27 kD protein (HSP27), (23 kD/6.0) IV Stress protein, chaperone, protection 12
Heat shock 70 protein (HSP70) (fragment),
(71 kD/5.4)
II Stress protein, chaperone, protection 12
Aldo-keto reductase (AKR), (36 kD/7.7) II Cytosolic enzyme in cellular detoxification
and protection
12.5
Glutathione S-transferase (GST), (23 kD/5.4) IV Cytosolic enzyme in cellular detoxification
and protection
12.2
Annexin A1 (39 kD/6.6) II Ca21 channels, combats inflammation,
suppress tumors
12.3
Annexin A2 (39 kD/7.6) II Ca21 channels, combats inflammation,
suppress tumors
14.8
Annexin A5 (36 kD/4.9) III Ca21 channels, combats inflammation,
suppress tumors
11.5
Manganese superoxide dismutase (MnSOD),
(23 kD/6.9)
V Anti-oxidant enzyme with tumor suppressor
activity, modulates mitochondrial signaling,
reduces mitochondrial damage
12.1
Voltage-dependent anion channel 2 (VDAC2),
(30 kD/6.8)
II Regulates apoptosis, a death signal-convergence
point
15.1
Mitochondrial ribosomal protein L13 (MRP-L13),
(21 kD/9.2)
VII Biosynthesis of mitochondrial proteins,
mitochondrial signaling.
13.1
Cyclophilin A (CyP-A), (18 kD/7.7) VII Involves intracellular signal transduction,
regulates pathways of T cell stimulation,
secreted by cells in response to inflammatory
stimuli.
12.3
Stratifin (14–3-3 sigma), (28 kD/4.7) III Chaperone, regulates signaling pathway,
tumor suppressor gene
12.8–
9.1
Galectin 7, 15 kD/7.0) VII Promotes apoptosis, functions through
JNK pathway
14.1
Actin, gamma (fragment), (42 kD/5.3) VI Cytoskelaten protein, involves cell proliferation 17.0
Cytokeratin 6B (CK-6B) (fragment), (60 kD/8.1) II Cytoskelaten protein, involves cell proliferation 14.8
4.2 Self defense in buccal SCC
Cells contain a number of antioxidant, antitoxic and anti-
inflammatory defenses [16, 17]. Aberrant increases in the
levels of proteins related to stress, detoxification, and
anti-oxidation in buccal SCC imply the stimulation of
cell defense systems in response to malignant transfor-
mation. HSPs are well-known antistress proteins. HSP
over-expression usually correlates with harmful insults
to the cell [18]. HSPs may offer a protective advantage
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Figure 5. Detailed alteration
patterns of proteins: annexin
A1, A2 and A5, MnSOD,
VDAC2, and MRP-L13.
Figure 6. Detailed alteration patterns of proteins: cyclo-
philin A (CyP-A), stratifin and galectin 7.
through their functions as molecular chaperones. In vitro
experiments have also demonstrated that HSP27 and
HSP70 protected mitochondria against injury by inhibit-
ing cytochrome c-mediated procaspase 9 processing
[19, 20]. In contrast, Cryst-B often displays a different
behavior in response to stress. Cryst-B has been shown
to negatively regulate cytochrome c- and caspase-8-
dependent activation of caspase-3 [21]. Reduced
expression of Cryst-B has been found in various tumors
[4, 22, 23]. The dramatic suppression of Cryst-B expres-
sion observed in the buccal SCC once again reflects the
distinctive role the protein plays which is different from
HSPs in the process of carcinogenesis. GST and aldo-
keto reductase (AKR) belong to two main cytosolic en-
zyme families involved in the detoxification processes.
GSTs catalyze the glutathione conjugation reaction with
eletrophilic compounds and carcinogens [24], while
AKRs catalyze the NADPH-dependent reduction of a
large variety of xenobiotic and endogenous toxic com-
pounds [25, 26]. n please check sentence n The up-
regulation of GST and AKR in buccal cancer corre-
sponds to the activation of self-protective mechanisms
in cells involved in the tumorigenetic processes. Over-
expression of GSTs and AKRs have also been detected
Figure 7. 2-DWestern blotting patterns show-
ing the different expression of annexin A2 and
its isoforms and cleaved fragments in normal
and SCC tissues.
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in other oral SCCs [27–29] and carcinomas [30–32]. These
proteins may therefore serve as potential tumor markers
and drug targets.
The elevation of manganese superoxide dismutase
(MnSOD) implies that the well-known antioxidant defense
system has been stimulated. Numerous studies have
suggested that MnSOD protects cells from injury and
suppresses tumor growth [33–35]. Over-expression of
MnSOD has even been tested as an anti-oral SCC ther-
apy [36–38]. Up-regulation of annexin A1, A2 and A5 is
another indicator of cell’s effort to protect itself. Annexins
are water soluble proteins that function as Ca21 channels
and regulate membrane fusion, a process underlying or-
ganelle biogenesis and cell division [39]. Although its
physiological function in vivo is largely unknown, in vitro
annexins exhibited anti-inflammatory [39, 40] and tumor
suppression activities [40, 41]. Several recent proteomic
studies identified significant over-expressed of annexin
A5 in head, neck and skin SCC tumors [42, 43], indicating
that it may be a specific SCC biomarker. In contrast
annexin A1 and A2 were found to have reduced expres-
sions in prostate [44, 45] and esophageal carcinomas [46,
47] but were up-regulated in head and neck SCC cells
[48]. These findings and our present observations sug-
gest that over-expression of annexin A1, A2 and A5 is a
phenomenon specific to oral SCC.
4.3 Mitochondrial-mediated apoptosis
The remarkable elevation in the expression of three mito-
chondrial proteins (voltage-dependent anion channel
VDAC) 2, MnSOD and MRP-L13) reflects the involvement
of mitochondrial mediated apoptosis in buccal carcino-
genesis. Recent studies on apoptosis signaling cascades
have revealed that mitochondria play a central role in reg-
ulating apoptosis [49–52]. The release of cytochrome c
and other proapoptotic proteins from mitochondria is an
important hallmark for apoptosis initiation. The release of
cytochrome c and proapoptotic protein takes place
through VDACs on the outer membranes of mitochondria,
signaling the activation of death-promoting proteolytic
enzymes known as caspases, which induce apoptosis.
n .. please rewrite sentence n VDACs serve as a death
signal-convergence point to facilitate the release of cyto-
chrome c and initiation of apoptosis by increasing expres-
sion levels. Mitochondrial VDACs have therefore been
proposed as therapeutic targets for triggering cell death
and thus suppressing tumor growth [53].
As stated above,MnSODcanprotect cells from injury. This
protection effect originates from the ability of MnSOD to
convert reactive oxygen species (ROS) which have been
implicated in signal transduction and carcinogenesis. In
cells, the mitochondrial respiratory chain is the major site
for ROS production [54, 55] and MnSOD is the major en-
zyme in mitochondria responsible for decomposition of
ROS [56, 57]. Mitochondrial ROS play an important role in
apoptosis because they can readily influence mitochon-
drial function without having to diffuse a long way from the
cytosol [58, 59]. It has been shown that MnSOD over-
expression alters the redox environment in mitochondria
and themetabolic capacity of the cell, leading to inhibition
of cell growth [60]. MRPs, together with two RNA mole-
cules, comprise the mitochondrial translation machinery
for the biosynthesis of proteins encoded by mitochondrial
DNA. The observed increases in mitochondrial proteins
may therefore be closely related to over-expression of
MRPs. Increasing data have demonstrated that MRPs are
also involved in apoptosis induction [61–63] and tumor
suppression [63, 64]. One MRP, death-associated protein
3, is actually a proapoptotic protein released from mito-
chondria [62], implying the direct involvement of MRPs in
mitochondrial mediated apoptosis.
4.4 Intracellular signaling pathways
The substantial up-regulation of the proteins cyclophilin A
(CyP-A), stratifin and galectin 7 provides evidence for the
involvement of intracellular signaling pathways in buccal
tumorigenesis. CyP-A is a member of the family of immu-
nophilin proteins, extensively studied for their role in cellu-
lar signaling pathways [65, 66]. By forming complexeswith
various immunosuppressive drugs, notably Cyclosporin
A, CyP-A inhibits T-cell receptor-mediated signal trans-
duction and thus regulates T cell activation [65, 67, 68].
CyP-A has also been shown to possess chaperone char-
acteristics: it is secreted by cells in response to inflamma-
tory stimuli and can modulate protein folding [66, 69]. The
numerous activities that CyP-A exerts in cellular growth
and differentiation, transcriptional control and cell signal-
ing suggests that it may play a unique role in an important
aspect of oncogenesis. CyP-A over-expression has
recently been detected in nonsmall cell lung cancer [70]
and hepatocellular carcinoma [71].
Stratifin, also a molecular chaperone, is known as tumor
suppressor protein 14-3-3 sigma. It plays significant roles
in a number of cellular activities, such as cell cycle pro-
gression, growth, differentiation and apoptosis, by regu-
lating various cytoplasm signaling pathways. Stratifin is a
negative cell cycle regulator that reduces cell growth by
causing G2 arrest [72, 73]. This activity, together with its
absence in breast cancer, suggests that it contributes to
breast tumor growth [72, 74]. In addition, decreased
expression of stratifin was found in neuroendocrine lung
tumors [75] and in bladder SCC [76]. However, a recent
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study revealed that stratifin is expressed at high levels in
several skin diseases including SCC [77]. We also
observed this unexpected phenomenon in the present
study with buccal SCC: strong stratifin over-expression
was observed for the intact molecule as well as all phos-
pharylated and truncated forms of stratifin. The patholog-
ical meanings of the different expressions of stratifin in
different cancers may be an intriguing subject for further
investigations. Galectin 7 is another apoptosis regulator
that functions intracellularly through the JNK signaling
pathway to influence cell growth and differentiation [78,
79]. Similar to its family member galectin 1, galectin 7
may also possess dual characteristics associated with
pro- and anti-tumoral activities at different stages of
tumor progression [80]. This explains why the expression
level of galectin 7 was significantly increased in chemi-
cally induced mammary carcinogenesis [81] but markedly
decreased in thyroid lesions of adenomas [80]. Recon-
ciled with the elevated expression of galectin 7 in well-dif-
ferentiated bladder SCC [76] and lymphoma [82], the
strong up-regulation of the protein in this study may
reflect the aggressiveness of buccal SCC.
5 Concluding remarks
Our current findings clearly demonstrated that multiple
pathways and systems are involved in SCC tumorigen-
esis. Both tumor antigens and tumor suppressor proteins
participate in the process of carcinogenesis, indicating
that cell defenses are initiated to fight malignant transfor-
mation. Global analyses of variations in protein expres-
sion in this study suggest that an imbalance between
apoptosis and cell proliferation may be a pathological
reason for buccal SCC. A combinational strategy which
simultaneously targets different pathways may be an
effective remedy to counter this disease. Candidates pro-
teins for targeting include SCC antigen, GNBP, GST,
MnSOD, annexins, VDAC, CyP-A, stratifin and galectin 7.
Although no specific biomarker for buccal SCC was
found in this study, the current success in identifying a
number of tumor-associated proteins proved that prote-
omic analysis can provide rich information to help under-
stand the pathology of a disease in an integrated way.
This type of information should lead to more rationally
designed diagnostic and treatment methods, which will
hopefully translate into improved patient outcome.
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